Evidence-based clinical practice: Overview of threats to the validity of evidence and how to minimise them, European Journal of Internal Medicine, vol.32, issue.11, pp.13-21, 2016. ,
DOI : 10.1016/j.ejim.2016.03.020
Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives, Intractable & Rare Diseases Research, vol.1, issue.1, pp.3-9, 2012. ,
DOI : 10.5582/irdr.2012.v1.1.3
Orphanet Report Series -Prevalence of rare diseases: Bibliographic data, Number 1, 2017. ,
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders, Journal of Comparative Effectiveness Research, vol.194, issue.9, pp.399-422, 2014. ,
DOI : 10.1002/9781118644898
A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov, Orphanet Journal of Rare Diseases, vol.71, issue.4, p.170, 2014. ,
DOI : 10.1111/j.1365-2125.2010.03877.x
on an action in the field of rare diseases, pp.1510007-1510017, 2009. ,
European Committee Expert Group on Rare Diseases Report on the State of the Art of Rare Disease Activities in Europe, p.15, 2014. ,
Orphanet Report Series -Lists of medicinal products for rare diseases in Europe, 2017. ,
Rare Disease and Orphan Drug Designated Approvals, 2016. ,
Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU, European Journal of Clinical Pharmacology, vol.68, issue.2, pp.1009-1033, 2012. ,
DOI : 10.1007/s00228-011-1115-3
European regulation on orphan medicinal products: 10 years of experience and future perspectives, Nat Rev Drug Discov, vol.10, issue.5, pp.341-350, 2011. ,
Novel Drugs Summary Available from: http://www.fda.gov/Drugs, 2015. ,
Latest news, 2016. ,
???Adaptive pathways??? to drug authorisation: adapting to industry?, BMJ, vol.354, 2016. ,
DOI : 10.1136/bmj.i4437
Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval, Clinical Pharmacology & Therapeutics, vol.374, issue.3, pp.426-463, 2012. ,
DOI : 10.1016/S0140-6736(10)60141-9
A European perspective - the European clinical research infrastructures network, Annals of Oncology, vol.22, issue.Suppl 7, pp.44-53, 2011. ,
DOI : 10.1093/annonc/mdr425
Barriers to the conduct of randomised clinical trials within all disease areas, Trials, vol.497, issue.7451, p.360, 2017. ,
DOI : 10.1038/497557a
URL : https://hal.archives-ouvertes.fr/inserm-01572262
Evidence-based practice within nutrition: what are the barriers for improving the evidence and how can they be dealt with?, Trials, vol.11, issue.10, p.425, 2017. ,
DOI : 10.1007/s11306-014-0750-y
URL : https://hal.archives-ouvertes.fr/inserm-01588782
Specific barriers to the conduct of randomised clinical trials on medical devices, Trials, vol.526, issue.7572, p.427, 2017. ,
DOI : 10.1038/526187a
URL : https://hal.archives-ouvertes.fr/inserm-01588783
Public Health and Rare Diseases: Oxymoron No More, Preventing Chronic Disease, vol.13, pp.5-15, 2016. ,
DOI : 10.5888/pcd13.150491
URL : https://www.cdc.gov/pcd/issues/2016/pdf/15_0491.pdf
International clinical trials setting for rare cancers: organisational and regulatory constraints???the EORTC perspective, ecancermedicalscience, vol.7, p.321, 2013. ,
DOI : 10.3332/ecancer.2013.321
Rare-disease genetics in the era of next-generation sequencing: discovery to translation, Nature Reviews Genetics, vol.48, issue.10, pp.681-91, 2013. ,
DOI : 10.1172/JCI44929
Disease registries in Europe, 2016. ,
Clinical Trials in Rare Disease, Journal of Child Neurology, vol.79, issue.1, pp.1142-50, 2013. ,
DOI : 10.1212/WNL.0b013e31826c19b4
Representation of rare diseases in health information systems: The orphanet approach to serve a wide range of end users, Human Mutation, vol.32, issue.5, pp.803-811, 2012. ,
DOI : 10.1002/humu.21469
The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases, Orphanet Journal of Rare Diseases, vol.8, issue.1, p.171, 2013. ,
DOI : 10.1212/WNL.0b013e318282334e
Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research?, Genetics in Medicine, vol.30, issue.2, pp.117-140, 2015. ,
DOI : 10.1186/1750-1172-7-37
Methodology of clinical trials for rare diseases, Best Practice & Research Clinical Rheumatology, vol.28, issue.2, pp.247-62, 2014. ,
DOI : 10.1016/j.berh.2014.03.004
A framework for applying unfamiliar trial designs in studies of rare diseases, Journal of Clinical Epidemiology, vol.64, issue.10, pp.1085-94, 2011. ,
DOI : 10.1016/j.jclinepi.2010.12.019
Statistical Challenges in the Evaluation of Treatments for Small Patient Populations, Science Translational Medicine, vol.376, issue.9742, pp.178-181, 2013. ,
DOI : 10.1016/S0140-6736(10)61121-X
Experimental designs for small randomised clinical trials: an algorithm for choice, Orphanet Journal of Rare Diseases, vol.8, issue.1, p.48, 2013. ,
DOI : 10.1007/s10985-007-9049-x
URL : https://hal.archives-ouvertes.fr/inserm-00818031
Innovative research methods for studying treatments for rare diseases: methodological review, BMJ, vol.349, issue.nov24 15, p.6802, 2014. ,
DOI : 10.1136/bmj.g6802
Power failure: why small sample size undermines the reliability of neuroscience, Nature Reviews Neuroscience, vol.80, issue.5, pp.365-76, 2013. ,
DOI : 10.1086/512821
How do you design randomised trials for smaller populations? A framework, BMC Medicine, vol.28, issue.2, p.183, 2016. ,
DOI : 10.1016/j.berh.2014.03.004
Directions for new developments on statistical design and analysis of small population group trials, Orphanet Journal of Rare Diseases, vol.8, issue.10, pp.78-94, 2016. ,
DOI : 10.1186/1750-1172-8-48
A framework: make it useful to guide and improve practice of clinical trial design in smaller populations, BMC Medicine, vol.11, issue.8, p.195, 2016. ,
DOI : 10.1186/s13023-016-0464-5
van der Tweel I. Sequential designs with small samples: evaluation and recommendations for normal responses, Stat Methods Med Res, 2016. ,
Optimal type I and type II error pairs when the available sample size is fixed, Journal of Clinical Epidemiology, vol.66, issue.8, pp.903-913, 2013. ,
DOI : 10.1016/j.jclinepi.2013.03.002
The clinically-integrated randomized trial: proposed novel method for conducting large trials at low cost, Trials, vol.59, issue.4, p.14, 2009. ,
DOI : 10.1016/S0025-7125(16)32001-6
Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design Available from, 2007. ,
Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size, European Journal of Cancer, vol.48, issue.9, pp.1386-91, 2012. ,
DOI : 10.1016/j.ejca.2011.12.024
A small n sequential multiple assignment randomized trial design for use in rare disease research, Contemporary Clinical Trials, vol.46, pp.48-51, 2015. ,
DOI : 10.1016/j.cct.2015.11.010
Evidence, eminence and extrapolation, Statistics in Medicine, vol.91, issue.3, pp.2117-2149, 2016. ,
DOI : 10.1038/clpt.2011.345
URL : http://onlinelibrary.wiley.com/doi/10.1002/sim.6865/pdf
Research methods to change clinical practice for patients with rare cancers, The Lancet Oncology, vol.17, issue.2, pp.70-80, 2016. ,
DOI : 10.1016/S1470-2045(15)00396-4
Orphan drug development is not taking off, British Journal of Clinical Pharmacology, vol.64, issue.5, pp.494-502, 2009. ,
DOI : 10.1111/j.1365-2125.2009.03369.x
URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2009.03369.x/pdf
Hepatology may have problems with putative surrogate outcome measures, Journal of Hepatology, vol.46, issue.4, pp.734-776, 2007. ,
DOI : 10.1016/j.jhep.2007.01.003
Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes, Statistics in Medicine, vol.89, issue.20 ,
DOI : 10.7326/0003-4819-118-9-199305010-00003
A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials, Statistical Methods in Medical Research, vol.5, issue.379, pp.205-241, 2009. ,
DOI : 10.1002/pst.207
Statistical approaches for evaluating surrogate outcomes in clinical trials: A systematic review, Journal of Biopharmaceutical Statistics, vol.27, issue.710, pp.1-21, 2015. ,
DOI : 10.1111/j.1541-0420.2011.01736.x
Letting post-marketing bridge the evidence gap: the case of orphan drugs: Table 1, BMJ, vol.353, 2016. ,
DOI : 10.1136/bmj.i2978
The thresholds for statistical and clinical significance ??? a five-step procedure for evaluation of intervention effects in randomised clinical trials, BMC Medical Research Methodology, vol.346, issue.1, p.34, 2014. ,
DOI : 10.1136/bmj.f839
Efficacy of prescribed injectable diacetylmorphine in the Andalusian trial: Bayesian analysis of responders and non-responders according to a multi domain outcome index, Trials, vol.3, issue.1, p.70, 2009. ,
DOI : 10.1186/1477-7517-3-16
Drug development for exceptionally rare metabolic diseases: challenging but not impossible, Orphanet Journal of Rare Diseases, vol.8, issue.1, p.179, 2013. ,
DOI : 10.1186/1750-1172-6-59
Pediatric Patient-Reported Outcome Instruments for Research to Support Medical Product Labeling: Report of the ISPOR PRO Good Research Practices for the Assessment of Children and Adolescents Task Force, Value in Health, vol.16, issue.4, pp.461-79, 2013. ,
DOI : 10.1016/j.jval.2013.04.004
How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice, British Journal of Clinical Pharmacology, vol.97, issue.4, pp.965-73, 2016. ,
DOI : 10.1002/cpt.59
The need for worldwide policy and action plans for rare diseases, Acta Paediatrica, vol.371, issue.8, pp.805-812, 2012. ,
DOI : 10.1016/S0140-6736(08)60875-2
Transparency and registration in clinical research in the Nordic countries (Report) Nordic Trial Alliance, NordForsk. Oslo. Norge, vol.2015, pp.1-108 ,
An in silico approach helped to identify the best experimental design, population, and outcome for future randomized clinical trials, Journal of Clinical Epidemiology, vol.69, pp.125-161, 2015. ,
DOI : 10.1016/j.jclinepi.2015.06.024
Good-quality research in rare diseases: trials and tribulations, Pediatric Nephrology, vol.327, issue.11, pp.217-240, 2016. ,
DOI : 10.1136/bmj.327.7405.47
Challenges for Academic Investigator???Initiated Pediatric Trials for Rare Diseases, Clinical Therapeutics, vol.36, issue.2, pp.184-90, 2014. ,
DOI : 10.1016/j.clinthera.2014.01.013
Meta-analysis of few small studies in orphan diseases, Research Synthesis Methods, vol.36, issue.1, pp.79-91, 2016. ,
DOI : 10.18637/jss.v036.i03
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis, Journal of Clinical Epidemiology, vol.61, issue.1, pp.64-75, 2007. ,
DOI : 10.1016/j.jclinepi.2007.03.013
False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review, BMJ Open, vol.6, issue.8, pp.11890-11906, 2016. ,
DOI : 10.1136/bmjopen-2016-011890
Trial sequential methods for meta-analysis, Research Synthesis Methods, vol.18, issue.7, pp.212-232, 2014. ,
DOI : 10.1002/(SICI)1097-0258(19990915/30)18:17/18<2271::AID-SIM254>3.0.CO;2-Z
How to Make More Published Research True, PLoS Medicine, vol.51, issue.7145, p.1001747, 2014. ,
DOI : 10.1371/journal.pmed.1001747.t002
URL : https://doi.org/10.1371/journal.pmed.1001747
Rescuing US biomedical research from its systemic flaws, Proceedings of the National Academy of Sciences, vol.10, issue.3, pp.5773-5780, 2014. ,
DOI : 10.1187/cbe.11-02-0013
URL : http://www.pnas.org/content/111/16/5773.full.pdf
Meta-research: Evaluation and Improvement of Research Methods and Practices, PLOS Biology, vol.505, issue.7485, pp.1002264-1002267, 2015. ,
DOI : 10.1371/journal.pbio.1002264.t002
Blinding during data analysis and writing of manuscripts, Controlled Clinical Trials, vol.17, issue.4, pp.285-90, 1996. ,
DOI : 10.1016/0197-2456(95)00263-4
Blind analysis: Hide results to seek the truth, Nature, vol.526, issue.7572, pp.187-196, 2015. ,
DOI : 10.1038/526187a
Blinded interpretation of study results can feasibly and effectively diminish interpretation bias, Journal of Clinical Epidemiology, vol.67, issue.7, pp.769-72, 2014. ,
DOI : 10.1016/j.jclinepi.2013.11.011